Form 20-F [X]
|
Form 40-F [ ]
|
Yes [ ]
|
No [X]
|
|
Number of
B shares
|
Average
purchase price
|
Transaction
value, DKK
|
Accumulated, last announcement
|
1,220,000
|
|
456,585,587
|
11 May 2015
|
200,000
|
374.80
|
74,960,180
|
12 May 2015
|
202,000
|
372.26
|
75,196,843
|
13 May 2015
|
200,000
|
369.14
|
73,828,540
|
18 May 2015
|
190,000
|
372.04
|
70,687,163
|
19 May 2015
|
190,000
|
379.52
|
72,108,591
|
Accumulated under the programme
|
2,202,000
|
|
823,366,904
|
Media: | ||
Anne Margrethe Hauge
|
+45 3079 3450
|
amhg@novonordisk.com
|
|
|
|
Investors: | ||
Kasper Roseeuw Poulsen
|
+45 3079 4303
|
krop@novonordisk.com
|
Daniel Bohsen
|
+45 3079 6376
|
dabo@novonordisk.com
|
Melanie Raouzeos
|
+45 3075 3479
|
mrz@novonordisk.com
|
Frank Daniel Mersebach (US)
|
+1 609 235 8567
|
fdni@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
24 25 67 90
|
Company announcement No 33 / 2015
|
Date: May 20, 2015
|
NOVO NORDISK A/S
Lars Rebien Sørensen,
Chief Executive Officer
|